- Home
- LPAA vs RNTX Comparison
LPAA vs RNTX Comparison
Compare LPAA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | RNTX |
|---|---|---|
| Founded | 2024 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 65.3M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LPAA | RNTX |
|---|---|---|
| Price | $10.77 | $0.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.1K | ★ 410.3K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $0.69 |
| 52 Week High | $11.67 | $2.18 |
Technical Indicators
Market Signals| Indicator | LPAA | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 57.58 |
| Support Level | $10.43 | $0.85 |
| Resistance Level | $10.80 | $0.88 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 6.74 | 84.53 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.